ArticleJournal of medicine and life2022
The anti-inflammatory and antioxidant effects of Montelukast on lung sepsis in adult mice.
Article in Journal of medicine and life, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Effect of montelukast on remission maintenance in patients with ulcerative colitis: a Randomized, double-blind controlled clinical trial.BMC gastroenterology · 2025Trial
- Ellagic acid and montelukast mitigate arsenic trioxide-induced hepatotoxicity via modulation of oxidative stress, inflammatory pathways, and mitochondrial apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeting Stearoyl-CoA Desaturase‑1 (SCD1) by the Drug-Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD.ACS omega · 2025Article
- Modulation of Neutrophil Recruitment and Inflammatory Signaling in Acute Respiratory Distress Syndrome by Leukotriene Inhibitors Montelukast and Zileuton.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- New insights on pharmacological potential of montelukast: a comprehensive review.Inflammopharmacology · 2025Review
- Repurposing High-Throughput Screening Reveals Unconventional Drugs with Antimicrobial and Antibiofilm Potential Against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Montelukast Sodium combined with Erythromycin Cyclocarbonate shows promoting effects on Mycoplasma pneumoniae infection in children.American journal of translational research · 2025Article
- The possible cardioprotective effect of ghrelin during experimental endotoxemia in mice.Journal of medicine and life · 2024Article
- Inhibition of sepsis-induced pancreatic injury by leukotriene receptor antagonism via modulation of oxidative injury, and downregulation of inflammatory markers in experimental rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Montelukast Influence on Lung in Experimental Diabetes.Medicina (Kaunas, Lithuania) · 2024Article
- L-valine derived from the gut microbiota protects sepsis-induced intestinal injury and negatively correlates with the severity of sepsis.Frontiers in immunology · 2024Article
- Targeting VEGF using Bevacizumab attenuates sepsis-induced liver injury in a mouse model of cecal ligation and puncture.Journal of medicine and life · 2023Article
- Lung protective effect of Ticagrelor in endotoxemia.Journal of medicine and life · 2023Article
- A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most complex clinical challenges facing medical practice is sepsis-induced lung dysfunction resulting from polymicrobial sepsis. Although many therapeutic approaches have been used in such clinical challenges, there is still further need for a new effective therapeutic approach. The objective of this study was to investigate if Montelukast could protect the lungs during polymicrobial sepsis by regulating inflammatory markers and the oxidative stress pathways. Twenty-four mature male Swiss-albino mice aged 8-12 weeks, with a weight of 20-30 g, were randomized into 4 equal groups (n=6), sham (laparotomy without cecal ligation and puncture (CLP)), CLP (laparotomy with CLP), vehicle 1 (equivalent volume of DMSO 1 hour prior to CLP), Montelukast (10 mg/kg IP 1 hour prior to CLP). Lung tissue pro-inflammatory mediators IL-6, IL-1β, IL-17, LTB-4 12(S) HETE, and oxidative stress were assessed using ELISA. The levels of F2 isoprostane were considerably greater in the sepsis group (p<0.05) as compared to the sham group, while Montelukast was significantly lower (p<0.05) in these inflammatory mediators and oxidative stress as compared to the sepsis group. Histologically, the lung tissue damage was significant (p<0.05) in all mice in the sepsis group, while Montelukast significantly reduced lung tissue injury (p<0.05). The current findings indicated that Montelukast could attenuate lung dysfunction during CLP-induced polymicrobial sepsis in male mice through their modulating effects on pro-inflammatory and oxidative stress downstream signalling pathways and subsequently decrease lung tissue cytokine concentrations (IL-1β, IL-6, IL-17, LTB-4, and 12(S)HETE).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.